Our look is new. Our purpose is the same. Learn more about our brand evolution.
The FSHD Society announced today that the U.S. Food and Drug Administration (FDA) has approved its application to hold an externally led Patient-Focused Drug Development (EL-PFDD) meeting on facioscapulohumeral muscular […]
https://www.youtube.com/watch?v=2GOgTBvu-GY The FSH Society is excited to celebrate the Third Annual World FSHD Day and join the global effort to raise awareness to FSHD on June 20, 2018. To build […]
[…] New Drug (IND) application for EPI-321, a first-of-its-kind epigenetic therapy targeting facioscapulohumeral muscular dystrophy ( FSHD). These milestones pave the way for global clinical trials of the therapy, which could […]
To coincide with World Rare Disease Day FSHD Patients across Europe say what they want from clinical trials Announcement by FSHD Europe Sheila Hawkins (far right), president of FSHD Europe […]
[…] of our battle plan to ensure patients will have access to treatments by June Kinoshita, FSHD Society When living with FSHD, the costs can add up: insurance and medical bills, […]
